Zepbound vs. Qsymia
See how Zepbound and Qsymia compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Zepbound is a once-weekly injection that combines two gut hormone pathways, while Qsymia is a daily pill combining a stimulant and an anticonvulsant.
Clinical trials show Zepbound produces greater average weight loss than Qsymia, but Zepbound costs several times more per month without insurance.
Qsymia is a controlled substance requiring REMS pharmacy enrollment, while Zepbound carries a boxed warning about thyroid tumor risk seen in animal studies.
Zepbound vs. Qsymia Drug Summary
Zepbound
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist injected under the skin once a week. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and separately for moderate-to-severe obstructive sleep apnea in adults with obesity.
Qsymia
Qsymia combines phentermine, a stimulant appetite suppressant, with topiramate, an anticonvulsant, in a single daily extended-release capsule. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 and older with obesity.
Zepbound vs. Qsymia Side Effects
Zepbound
Qsymia
Zepbound vs. Qsymia Dosage
Zepbound
Qsymia
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 3.75 mg/23 mg once daily | Days 1-14 |
| Maximum dose | 15 mg/92 mg once daily | Week 17 onward |
| Dose changes | 3 increases | As tolerated |
Zepbound
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Qsymia
| STAGE | DOSE | WHEN |
| Starting dose | 3.75 mg/23 mg once daily | Days 1-14 |
| Maximum dose | 15 mg/92 mg once daily | Week 17 onward |
| Dose changes | 3 increases | As tolerated |
Zepbound vs. Qsymia Indications
Zepbound
Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight adults with at least one weight-related condition like high blood pressure or type 2 diabetes. It also has a separate approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Both uses call for pairing the medication with a reduced-calorie diet and more physical activity.
Obesity (BMI 30 or higher)
Overweight (BMI 27+) plus a weight-related condition
Moderate-to-severe obstructive sleep apnea with obesity
Used alongside diet and exercise
Qsymia
Qsymia is FDA-approved for chronic weight management in adults with obesity, or overweight adults with at least one weight-related condition. It is also approved for adolescents 12 and older with obesity. Like Zepbound, it is meant to be used along with a reduced-calorie diet and increased physical activity.
Obesity (BMI 30 or higher) in adults
Overweight (BMI 27+) plus a weight-related condition
Obesity in adolescents 12 and older
Used alongside diet and exercise
Zepbound vs. Qsymia Pros and Cons
Zepbound
Zepbound produced some of the largest average weight-loss results seen in obesity drug trials, and it is the only medication also approved for obstructive sleep apnea. It requires a weekly self-injection and typically costs far more out of pocket than oral options like Qsymia.
Pros
Larger average weight loss than Qsymia in trials
Only medication also approved for sleep apnea
Dosed just once a week
Not a controlled substance
Cons
Requires self-injection, not a pill
Common GI side effects like nausea and diarrhea
Roughly $1,050 to $1,100 per month without insurance
Boxed warning for thyroid tumor risk seen in animal studies
Qsymia
Qsymia has been on the market since 2012 and is taken as a daily pill instead of an injection. It tends to produce more modest weight loss than Zepbound and comes with its own restrictions, including REMS pharmacy enrollment and monthly pregnancy testing.
Pros
Oral capsule, no injections needed
Roughly $200 to $350 per month without insurance
Longer track record, approved since 2012
Also approved for adolescents 12 and older
Cons
Schedule IV controlled substance with abuse potential
Requires REMS enrollment and certified pharmacies
Not for people with glaucoma or hyperthyroidism
More modest average weight loss than Zepbound
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.